Injective Labs
Injective Labs runs a Layer-1 blockchain built for on-chain derivatives and tokenized finance.
On the record
Checkpoint: SEC decision on Injective's Form TA-1 transfer-agent registration
The call
Injective has the paperwork and the partners for institutional finance, but Hyperliquid is winning the actual derivatives trade right now.
Injective Labs built a blockchain designed to let people trade futures and derivatives on-chain, and it has backing from big names like Robinhood and Coinbase. The problem is that Hyperliquid, a competing platform, is already doing the same thing better and taking away most of the trading volume. Injective makes almost no money from its blockchain right now, only about $1,500 per day in fees, even though investors say it is worth over $500 million. The one thing that could change this is if the SEC approves Injective's plan to become an official transfer agent, which would let it handle more regulated financial products, but that approval is still pending and not guaranteed.
Why
01
AI pressure: None apparent. No AI lab or agent is named as eating this business; the pressure so far is from a rival blockchain, not AI trading tools. Could AI do the core job? Only partly.
02
Bigger players: Hyperliquid. Hyperliquid already runs 44-70% of on-chain perp volume and pulled in roughly $844M in 2025 revenue while Injective's fees stay near zero. Could a giant copy it? Yes, easily.
03
What protects it. Filed regulatory status (SEC transfer-agent, CFTC futures, MiCA) plus validator ties to Deutsche Telekom, BitGo, and Kraken give it institutional cover Hyperliquid lacks.
What would change this call
SEC decision on Injective's Form TA-1 transfer-agent registration, filed July 16 2026. Shows whether the regulatory moat becomes real revenue or stays a filing.
Hyperliquid, Lighter, and Aster's share of on-chain perp volume over the next two quarters. Shows whether Injective keeps losing derivatives share to faster-moving peers.
Whether Injective closes a new institutional equity round at a disclosed valuation. Shows whether investors still back Injective at or above its 2023 $1.3B mark.
Hyperliquid, Lighter, and Aster's share of on-chain perp volume over the next two quarters. Shows whether Injective keeps losing derivatives share to faster-moving peers.
Whether Injective closes a new institutional equity round at a disclosed valuation. Shows whether investors still back Injective at or above its 2023 $1.3B mark.
Key numbers
- Protocol fees ~$1,500/day vs market cap over $500M
- TVL just $8.37M
- No new equity round disclosed since 2023's $150M fund
Named risks
- Core on-chain derivatives use case losing share to Hyperliquid, Lighter and Aster.
- Protocol fee revenue (~$1,500/day) is tiny relative to market cap, creating a narrative-valuation gap.
- SEC Form TA-1 transfer-agent registration filed July 16, 2026 but not yet approved.
- No fresh institutional equity valuation disclosed since January 2023.
- Headcount estimates inconsistent across trackers (43 to 99), signaling limited independent verification of company scale.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Hyperliquid | losing to | ~$844M 2025 revenue and 44-70% of decentralized perp share through 2025 (vendor/analyst data as of 2026-05-13) |
| Lighter | losing to | Cited as share-gainer against Injective's perp use case as Hyperliquid share fell mid-2026 |
| Aster | losing to | Named alongside Lighter as a perp-market share gainer by mid-2026 |
| dYdX | contesting | Cosmos-appchain perp incumbent with ~$300-400M TVL as of 2026-06-13, smaller than Hyperliquid but a direct peer |
| Ethereum | contesting | Remains the largest smart-contract/DeFi settlement layer that Injective competes with for liquidity and developers |
Questions people ask
- Is Injective Labs profitable in 2026?
- Not by conventional measures. As of July 19, 2026, Injective's own on-chain protocol fees ran about $1,500 per day, against a market cap fluctuating between roughly $450M and $730M, a gap one analysis called narrative-driven rather than revenue-driven.
- Could AI replace Injective Labs?
- Unlikely to replace the base-layer blockchain itself, but AI could compress its trading and dev-tooling edge. Injective launched an AI Agent SDK and joined the x402 Foundation on July 16, 2026, positioning itself as AI-agent infrastructure rather than a target for replacement.
- Who is Injective's biggest competitor?
- Hyperliquid, a purpose-built perpetuals L1 that generated roughly $844M in 2025 revenue and held 44-70% of decentralized perp market share through 2025, directly out-executing Injective's core derivatives use case.
- Who owns Injective Labs?
- Injective Labs is privately held, founded in 2018 by Eric Chen and Albert Chon through Binance Labs' first incubation program, and backed by investors including Pantera Capital, Jump Crypto, Brevan Howard Digital, Kraken Ventures and KuCoin Ventures across rounds through January 2023.
- Will the SEC approve Injective's transfer agent registration?
- Unknown as of this writing. Injective filed SEC Form TA-1 to register as a transfer agent for tokenized securities on July 16, 2026, alongside a Washington D.C. summit, but approval or rejection was still pending as of the filing date.
- Is the INJ token a good investment right now?
- As of July 19, 2026, INJ traded roughly 90% below its March 2024 all-time high of about $52.62, with market cap swinging between $450M and $730M, while pending Canary Capital and 21Shares ETF filings remain binary near-term catalysts.
Timeline
- 2026-07-20Coinbase paused deposits/withdrawals during INJ mainnet migration
- 2026-07-16DC Summit: Robinhood listing, SEC Form TA-1 filed, x402 Foundation join, AI Agent SDK, MiCA whitepaper
- 2026-05-21Injective Policy Institute launched in Washington D.C.
- 2026-04-15First US-regulated INJ futures launched on CFTC-regulated Bitnomial Exchange
- 2026-01-20INJ Supply Squeeze announced, doubling token deflation burn rate
- 2025-11-11Native EVM mainnet launch with 30-40+ dApps live
- 2024-08-26HQ relocated to 205 West 28th Street, NYC
- 2023-01-26$150M ecosystem fund announced backed by Kraken, Pantera, Jump Crypto
- 2018Founded by Eric Chen and Albert Chon via Binance Labs incubation program
Revision history
21 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Injective (blockchain) (2026-05-11)
- Injective Labs Moving to Bigger Offices at 205 West 28th Street (2024-08-26)
- Blockchain Startup Injective Nets $40M Round Featuring Jump Crypto, BH Digital
- Injective Labs Secures $150M in Funding (2023-01-26)
- Layer 1 Blockchain Infrastructure for Finance
- Valuation, Funding, Investors (2026-07-08)
- The Injective Ninja Roundup of 2025 (2026-01-06)
- Injective Price: INJ/USD Live Price Chart (2026-07-19)
- Injective rolls out native EVM support on its high-performance Cosmos-based chain (2025-11-11)
- Injective Introduces the INJ Supply Squeeze (2026-01-20)
- INJ Is Officially Live For Trading on Binance.US (2026-07-07)
- Injective highlights SEC registration, Robinhood listing (2026-07-19)